The effectiveness of the first therapeutic drug to target annexin-A1 – a protein overexpressed in several cancer types that promotes the progression of tumour – has been demonstrated in a new study involving Anglia Ruskin University researchers. High annexin-A1 expression levels are associated with poorer survival rates for patients with various cancers that so far have limited treatment options, including triple-negative breast, pancreatic, colorectal and prostate cancers. MDX-124, a monoclonal antibody therapy being developed for use in immunotherapy by Scottish biotech company Medannex, has…